The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Papakonstantinou N, Ntoufa S, Chartomatsidou E, Kotta K, Agathangelidis A, Giassafaki L, Karamanli T, Bele P, Moysiadis T, Baliakas P, Sutton LA, Stavroyianni N, Anagnostopoulos A, Makris AM, Ghia P, Rosenquist R, Stamatopoulos K.
Papakonstantinou N, et al. Among authors: ntoufa s.
Oncotarget. 2016 Jun 14;7(24):35946-35959. doi: 10.18632/oncotarget.9371.
Oncotarget. 2016.
PMID: 27191993
Free PMC article.